Patient Selection for Premenopausal Endocrine Therapy

July 23, 2015
Hope S. Rugo, MD

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses patient selection for premenopausal endocrine therapy.

Rugo mentions that it is key for women to have estrogen receptors, as well as progesterone receptors. The selection process is mainly based on clinical risk. However, age is also a factor. Rugo explains the fact that younger patients benefit from ovarian suppression more than older patients.

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses patient selection for premenopausal endocrine therapy.